Top ▲

Search results

Page 1 of 8

Your search for atherosclerosis returned 72 results

Order results by:
Download as a CSV:
Ligand: darapladib
Comments: clinical drug candidates with potential to reduce the risk of atherosclerosis and associated clinical sequelae .
Clinical use: atherosclerosis, but it failed to meet clinical primary end points and GSK has discontinued further
Immuno Ligand Comments: that may be relevant in conditions other than atherosclerosis that also have an inflammatory component .
Target: regulator of G-protein signaling 1 (R4 family)
Mutations/pathophysiology - disease: Atherosclerosis susceptibility
Mutations/pathophysiology - comment: Vascular diseases: Atherosclerosis AND aortic aneurysms
Disease: Atherosclerosis susceptibility
Disease Name: Atherosclerosis susceptibility
Pathophysiology comments: Vascular diseases: Atherosclerosis AND aortic aneurysms
Ligand: inclacumab
Comments: atherosclerosis. It blocks the interaction between selectin P and its primary ligand, P-selectin glycoprotein
Clinical use: atherosclerosis has been terminated. Global Blood Therapeutics redirected development to determine the efficacy of inclacumab
Target: GPR132 (Class A Orphans)
Consequences of altering gene expression: atherosclerosis in low-density lipoprotein receptor knockout mice. Reduction in aortic lesion coverage, macrophage accumulation
Consequences of altering gene expression: deficiency affects atherosclerosis in a tissue-specific manner. ApoE dependent pro-atherogenic phenotype is observed
Consequences of altering gene expression: ability to engulf apoptotic cells in vitro, and promotes macrophage activation and atherosclerosis in vivo
Consequences of altering gene expression - comment: atherosclerosis. One study investigating GPR132 knockout in LDLR-/- and ApoE-/- mice, suggested an ApoE-dependent
Ligand: methotrexate
Immuno Ligand Comments: atherosclerosis; it did not reduce the number of cardiovascular events, or reduce inflammation markers such
Target: sphingomyelin synthase 2 (Sphingomyelin synthase)
Receptor Immuno Comment: atherosclerosis, fatty liver and insulin resistance. Since downregulation of SMS2 activity results in protective effects
Target: mixed lineage kinase domain like pseudokinase (TKL-unique family)
Receptor Immuno Comment: atherosclerosis, acute colitis, psoriasis and atherosclerosis . The receptor interacting protein kinases RIPK1 and RIPK3 , and pseudokinase
Ligand: VIP {Sp: Human, Mouse, Rat}
Immuno Ligand Comments: atherosclerosis model, the anti-inflammatory effects of VIP included a reduction in Th1-driven inflammatory
Ligand: canakinumab
Immuno Ligand Comments: atherosclerosis. Results from the CANTOS trial (NCT01327846) showed that canakinumab (in high-risk patients; in addition

1 2 3 4 5 6 7 8

Target search page
Ligand search page
Pharmacology search page